Literature DB >> 15315859

A comparative evaluation of nasal and parenteral vaccine adjuvants to elicit systemic and mucosal HIV-1 peptide-specific humoral immune responses in cynomolgus macaques.

Michael A Egan1, Siew Yen Chong, Michael Hagen, Shakuntala Megati, Eva B Schadeck, Priscilla Piacente, Ben-Jiang Ma, David C Montefiori, Barton F Haynes, Zimra R Israel, John H Eldridge, Herman F Staats.   

Abstract

Cynomolgus macaques were immunized by either the intramuscular (i.m.) or intranasal (i.n.) route with a HIV-1 peptide-based immunogen (C4-V3 89.6P) alone, or formulated with novel adjuvants to evaluate the ability of the adjuvants to augment peptide-specific systemic and mucosal immune responses. A mutant cholera toxin, CT-E29H, or the combination of recombinant human IL-1alpha (rhIL-1alpha) protein and recombinant human GM-CSF (rhGM-CSF) protein were tested as adjuvants for i.n. immunization, while a stable emulsion of a synthetic monophosphoryl lipid A (MPL) analogue (RC529-SE) plus rhGM-CSF protein was tested as an adjuvant for i.m. immunization. Macaques immunized i.n. with peptide alone failed to elicit an anti-C4-V3 89.6P antibody response in serum. In contrast, all the tested peptide/adjuvant formulations elicited peptide-specific immune responses. RC529-SE/rhGM-CSF elicited the highest peak anti-peptide IgG geometric mean titer in serum (1:32,768 at week 25) followed by rhIL-1alpha/rhGM-CSF (1:1217 at week 10) and CT-E29H (1:256 at week 25). Measurable SHIV neutralizing antibody responses were detectable in only one macaque immunized i.m. with peptide formulated with RC529-SE/rhGM-CSF. Macaques immunized by the i.n. route with peptide in combination with CT-E29H failed to elicit measurable antibody responses at nasal or genital mucosal surfaces. In contrast, antibody responses at the nasal and genital mucosa were detected in macaques immunized by the i.n. route with peptide in combination with rhIL-1alpha/rhGM-CSF. However, antibody responses at the nasal and genital mucosa were highest in macaques immunized parenterally with peptide in combination with the adjuvants RC529-SE/rhGM-CSF. These results suggest that parenteral vaccine administration in combination with the appropriate adjuvant formulation can elicit vaccine-specific humoral immune responses in both systemic and mucosal compartments.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15315859     DOI: 10.1016/j.vaccine.2004.03.011

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  20 in total

1.  Effective induction of protective systemic immunity with nasally administered vaccines adjuvanted with IL-1.

Authors:  William M Gwinn; Shaun M Kirwan; Sheena H Wang; Kathleen A Ashcraft; Neil L Sparks; Catherine R Doil; Tom G Tlusty; Leslie S Casey; Susan K Hollingshead; David E Briles; Richard S Dondero; Anthony J Hickey; W Michael Foster; Herman F Staats
Journal:  Vaccine       Date:  2010-08-17       Impact factor: 3.641

2.  Mucosal and systemic adjuvant activity of alphavirus replicon particles.

Authors:  Joseph M Thompson; Alan C Whitmore; Jennifer L Konopka; Martha L Collier; Erin M B Richmond; Nancy L Davis; Herman F Staats; Robert E Johnston
Journal:  Proc Natl Acad Sci U S A       Date:  2006-02-27       Impact factor: 11.205

3.  Common features of mucosal and peripheral antibody responses elicited by candidate HIV-1 vaccines in rhesus monkeys.

Authors:  Hualin Li; Kathryn E Stephenson; Zi Han Kang; Christy L Lavine; Michael S Seaman; Dan H Barouch
Journal:  J Virol       Date:  2014-09-10       Impact factor: 5.103

4.  Which comes first: the antigen or the adjuvant?

Authors:  Sallie R Permar; Herman F Staats
Journal:  J Clin Invest       Date:  2014-05-16       Impact factor: 14.808

5.  Parenteral Vaccination Can Be an Effective Means of Inducing Protective Mucosal Responses.

Authors:  John D Clements; Lucy C Freytag
Journal:  Clin Vaccine Immunol       Date:  2016-06-06

6.  Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection.

Authors:  Timothy R Fouts; Kenneth Bagley; Ilia J Prado; Kathryn L Bobb; Jennifer A Schwartz; Rong Xu; Robert J Zagursky; Michael A Egan; John H Eldridge; Celia C LaBranche; David C Montefiori; Hélène Le Buanec; Daniel Zagury; Ranajit Pal; George N Pavlakis; Barbara K Felber; Genoveffa Franchini; Shari Gordon; Monica Vaccari; George K Lewis; Anthony L DeVico; Robert C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-13       Impact factor: 11.205

7.  Maximal adjuvant activity of nasally delivered IL-1α requires adjuvant-responsive CD11c(+) cells and does not correlate with adjuvant-induced in vivo cytokine production.

Authors:  Afton L Thompson; Brandi T Johnson; Gregory D Sempowski; Michael D Gunn; Baidong Hou; Anthony L DeFranco; Herman F Staats
Journal:  J Immunol       Date:  2012-02-15       Impact factor: 5.422

8.  Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial.

Authors:  Paul Spearman; Spyros Kalams; Marnie Elizaga; Barbara Metch; Ya-Lin Chiu; Mary Allen; Kent J Weinhold; Guido Ferrari; Scott D Parker; M Juliana McElrath; Sharon E Frey; Jonathan D Fuchs; Michael C Keefer; Michael D Lubeck; Michael Egan; Ralph Braun; John H Eldridge; Barton F Haynes; Lawrence Corey
Journal:  Vaccine       Date:  2008-11-07       Impact factor: 3.641

9.  Nonmucosal alphavirus vaccination stimulates a mucosal inductive environment in the peripheral draining lymph node.

Authors:  Joseph M Thompson; Michael G Nicholson; Alan C Whitmore; Melodie Zamora; Ande West; Akiko Iwasaki; Herman F Staats; Robert E Johnston
Journal:  J Immunol       Date:  2008-07-01       Impact factor: 5.422

10.  Differential immunogenicity of vaccinia and HIV-1 components of a human recombinant vaccine in mucosal and blood compartments.

Authors:  Peter A Anton; F Javier Ibarrondo; W John Boscardin; Ying Zhou; Elissa J Schwartz; Hwee L Ng; Mary Ann Hausner; Roger Shih; Julie Elliott; Patricia M Hultin; Lance E Hultin; Charles Price; Marie Fuerst; Amy Adler; Johnson T Wong; Otto O Yang; Beth D Jamieson
Journal:  Vaccine       Date:  2008-06-17       Impact factor: 3.641

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.